## Libero Vitiello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7189303/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regulatory mutations in transforming growth factor-?3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovascular Research, 2005, 65, 366-373.	1.8	364
2	Convenience versus Biological Significance: Are PMA-Differentiated THP-1 Cells a Reliable Substitute for Blood-Derived Macrophages When Studying in Vitro Polarization?. Frontiers in Pharmacology, 2018, 9, 71.	1.6	180
3	<i>In vivo</i> tissue engineering of functional skeletal muscle by freshly isolated satellite cells embedded in a photopolymerizable hydrogel. FASEB Journal, 2011, 25, 2296-2304.	0.2	161
4	Cardiac involvement in becker muscular dystrophy. Journal of the American College of Cardiology, 1993, 22, 1927-1934.	1.2	124
5	Macrophage-secreted myogenic factors: a promising tool for greatly enhancing the proliferative capacity of myoblasts in vitro and in vivo. Neurological Sciences, 2002, 23, 189-194.	0.9	111
6	Dystrophin-positive fibers in duchenne dystrophy: Origin and correlation to clinical course. Muscle and Nerve, 1995, 18, 1115-1120.	1.0	68
7	Satellite Cells Delivered by Micro-Patterned Scaffolds: A New Strategy for Cell Transplantation in Muscle Diseases. Tissue Engineering, 2007, 13, 253-262.	4.9	62
8	Loss-of-Function Mutation of the <i>GPR40</i> Gene Associates with Abnormal Stimulated Insulin Secretion by Acting on Intracellular Calcium Mobilization. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3541-3550.	1.8	61
9	Electrophysiologic stimulation improves myogenic potential of muscle precursor cells grown in a 3D collagen scaffold. Neurological Research, 2008, 30, 207-214.	0.6	56
10	Prevalence of dystrophin-positive fibers in 85 duchenne muscular dystrophy patients. Neuromuscular Disorders, 1992, 2, 41-45.	0.3	55
11	Transfection of cultured myoblasts in high serum concentration with DODAC:DOPE liposomes. Gene Therapy, 1998, 5, 1306-1313.	2.3	53
12	Familial temporal lobe epilepsy with psychic auras associated with a novel <i>LGI1</i> mutation. Neurology, 2011, 76, 1173-1176.	1.5	49
13	Modeling Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D Cultures. International Journal of Molecular Sciences, 2020, 21, 3404.	1.8	46
14	Efficient Delivery of Human Single Fiber-Derived Muscle Precursor Cells via Biocompatible Scaffold. Cell Transplantation, 2008, 17, 577-584.	1.2	42
15	Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: Threshold effect for deletion size?. Muscle and Nerve, 1996, 19, 1154-1160.	1.0	40
16	A novel murine model for arrhythmogenic cardiomyopathy points to a pathogenic role of Wnt signalling and miRNA dysregulation. Cardiovascular Research, 2019, 115, 739-751.	1.8	40
17	The Glucose-Dependent Insulinotropic Polypeptide Receptor is Overexpressed Amongst GNAS1 Mutation-Negative Somatotropinomas and Drives Growth Hormone (GH)-Promoter Activity in GH3 Cells. Journal of Neuroendocrinology, 2011, 23, 641-649.	1.2	39
18	A 3′ consensus splice mutation in the human dystrophin gene detected by a screening for intra-exonic deletions. Human Molecular Genetics, 1992, 1, 345-346.	1.4	35

LIBERO VITIELLO

#	Article	IF	CITATIONS
19	Analysis of Differential Lipofection Efficiency in Primary and Established Myoblasts. Molecular Therapy, 2002, 5, 161-169.	3.7	35
20	Genomic Organization of the Human Dystrophin Gene across the Major Deletion Hot Spot and the 3′ Region. Genomics, 1995, 28, 97-100.	1.3	33
21	A Novel Loss-of-Function LGI1 Mutation Linked to Autosomal Dominant Lateral Temporal Epilepsy. Archives of Neurology, 2008, 65, 939-42.	4.9	33
22	Patterns of deletions of the dystrophin gene in different European populations. Human Genetics, 1993, 91, 342-6.	1.8	32
23	Biofabricating murine and human myoâ€substitutes for rapid volumetric muscle loss restoration. EMBO Molecular Medicine, 2021, 13, e12778.	3.3	29
24	In vivo delivery of naked antisense oligos in aged mdx mice: Analysis of dystrophin restoration in skeletal and cardiac muscle. Neuromuscular Disorders, 2008, 18, 597-605.	0.3	27
25	Revertant Fibers in the mdx Murine Model of Duchenne Muscular Dystrophy: An Age- and Muscle-Related Reappraisal. PLoS ONE, 2013, 8, e72147.	1.1	27
26	De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle. Acta Biomaterialia, 2021, 132, 227-244.	4.1	26
27	Three-dimensional porous scaffold allows long-term wild-type cell delivery in dystrophic muscle. Journal of Tissue Engineering and Regenerative Medicine, 2011, 5, 1-10.	1.3	25
28	The LGI1/Epitempin gene encodes two protein isoforms differentially expressed in human brain. Journal of Neurochemistry, 2006, 98, 985-991.	2.1	24
29	Screening for mutations in the muscle promoter region and for exonic deletions in a series of 115 DMD and BMD patients Journal of Medical Genetics, 1992, 29, 127-130.	1.5	23
30	The Rag2–ll2rb–Dmd– Mouse: a Novel Dystrophic and Immunodeficient Model to Assess Innovating Therapeutic Strategies for Muscular Dystrophies. Molecular Therapy, 2013, 21, 1950-1957.	3.7	23
31	Secretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors. PLoS Genetics, 2016, 12, e1006376.	1.5	23
32	SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells. Human Molecular Genetics, 2017, 26, 3342-3351.	1.4	23
33	Reappraisal of the Incidence Rate of Duchenne and Becker Muscular Dystrophies on the Basis of Molecular Diagnosis. Neuroepidemiology, 1993, 12, 326-330.	1.1	22
34	3D Printed Graphene-PLA Scaffolds Promote Cell Alignment and Differentiation. International Journal of Molecular Sciences, 2022, 23, 1736.	1.8	21
35	Selection of multipotent cells and enhanced muscle reconstruction by myogenic macrophage-secreted factors. Experimental Cell Research, 2009, 315, 915-927.	1.2	20
36	Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma. Clinical Endocrinology, 2003, 59, 707-715.	1.2	19

LIBERO VITIELLO

#	Article	IF	CITATIONS
37	A novel nonsense mutation in the human dystrophin gene. Human Mutation, 1993, 2, 314-316.	1.1	18
38	Engineering a 3D in vitro model of human skeletal muscle at the single fiber scale. PLoS ONE, 2020, 15, e0232081.	1.1	18
39	A study on duplications of the dystrophin gene: Evidence of a geographical difference in the distribution of breakpoints by intron. Human Genetics, 1994, 94, 83-87.	1.8	17
40	Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma. Histology and Histopathology, 2010, 25, 551-60.	0.5	16
41	A targeted next-generation gene panel reveals a novel heterozygous nonsense variant in the TP63 gene in patients with arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, 773-780.	0.3	15
42	Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy. International Journal of Molecular Sciences, 2019, 20, 6053.	1.8	14
43	Commitment of Autologous Human Multipotent Stem Cells on Biomimetic Poly-L-Lactic Acid-Based Scaffolds Is Strongly Influenced by Structure and Concentration of Carbon Nanomaterial. Nanomaterials, 2020, 10, 415.	1.9	14
44	Murine Muscle Precursor Cells Survived and Integrated in a Cryoinjured Gastroesophageal Junction. Journal of Surgical Research, 2007, 143, 253-259.	0.8	11
45	Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in mdx Mice and in Myogenic Cultures From DMD Patients. Frontiers in Physiology, 2018, 9, 1087.	1.3	11
46	Chronic Systemic Curcumin Administration Antagonizes Murine Sarcopenia and Presarcopenia. International Journal of Molecular Sciences, 2021, 22, 11789.	1.8	9
47	Occurrence of two different intragenic deletions in two male relatives affected with Duchenne muscular dystrophy. American Journal of Medical Genetics Part A, 1994, 50, 84-86.	2.4	8
48	Duplication of dystrophin gene and dissimilar clinical phenotype in the same family. Neuromuscular Disorders, 1995, 5, 475-481.	0.3	8
49	Macrophage-secreted factors enhance thein vitroexpansion of DMD muscle precursor cells while preserving their myogenic potential. Neurological Research, 2010, 32, 55-62.	0.6	8
50	Gene transfer in skeletal muscle by systemic injection of DODAC lipopolyplexes. Neurological Sciences, 2000, 21, S967-S969.	0.9	7
51	Designing a 3D printed human derived artificial myo-structure for anal sphincter defects in anorectal malformations and adult secondary damage. Materials Today Communications, 2018, 15, 120-123.	0.9	7
52	Novel Missense Variant in <i>MYL2</i> Gene Associated With Hypertrophic Cardiomyopathy Showing High Incidence of Restrictive Physiology. Circulation Genomic and Precision Medicine, 2020, 13, e002824.	1.6	6
53	DXS997 localized to intron 48 of dystrophin. Human Molecular Genetics, 1993, 2, 2199-2199.	1.4	5
54	Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy. Cells, 2021, 10, 2578.	1.8	5

LIBERO VITIELLO

#	Article	IF	CITATIONS
55	Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases. International Journal of Molecular Sciences, 2021, 22, 10985.	1.8	5
56	Detection of unknown gene mutations by multiplex single-strand conformation polymorphism (MSSCP) Genome Research, 1993, 3, 60-62.	2.4	3
57	Tuning the Consonance of Microscopic Neuro-Cardiac Interactions Allows the Heart Beats to Play Countless Genres. Frontiers in Physiology, 2022, 13, 841740.	1.3	3
58	Gene therapy for duchenne muscular dystrophy — Early experiences with liposome-mediated gene transfer. Transfusion Science, 1996, 17, 63-69.	0.6	1
59	Sciences within European Young Researcher Community2/21he neuro-cardiac interaction defines an extracellular microdomain required for neurotrophic signaling273Gut microbiota is important in the development of angiotensin II driven arterial hypertension and vascular dysfunction in mice274Role of the mitochondrial protein Opa1 in the regulation of the cardiac sympathetic neuron physiology.	1.8	1
60	A novel murine model for arrhythmogenic cardiomyopathy points to a pathogenic role of Wnt/β-catenin signaling and miRNA dysregulation. Journal of Molecular and Cellular Cardiology, 2018, 120, 51-52.	0.9	1